The Best Big Biotech for 2013

Which company is the best big biotech for 2013? Several of the major players recently presented at the 31st annual JPMorgan Healthcare Conference.  Sifting through the information that the companies shared helps us to determine who takes the prize. Here are highlights for the top four contenders.

Amgen (NASDAQ: AMGN  )
Amgen CEO Bob Bradway noted that 2013 will be the last year that the company splits profits on Enbrel with Pfizer (NYSE: PFE  ) . Beginning next year, the agreement switches to a royalty model, which means Amgen will make more from sales of the drug. On the negative side, Bradway acknowledged that "there will be new competition in the anti-inflammation space." 

Several other Amgen products are coming on strong. Prolia/XGEVA are on track to top $1 billion in sales for 2012. Bradway also referenced solid growth for new products in the company's lineup: Sensipar, Nplate and Vectibix. The recent fiscal cliff deal helped prospects for Sensipar by keeping the drug out of end-stage renal disease bundles through 2016.

Regarding Amgen's pipeline, Bradway highlighted several phase 3 cancer drugs. Initial results from phase 3 studies for AMG386 in the treatment of ovarian cancer and T-VEC, which targets malignant melanoma, are expected in 2013. Another promising oncology drug, AMG102, has a phase 3 trial under way for the treatment of gastric cancer. Bradway also expressed great expectations for AMG145, a cholesterol drug advancing to phase 3. 

Biogen Idec (NASDAQ: BIIB  )
Biogen Idec CEO George Scangos pointed out that the company's leading product, Avonex, had been losing market share but is now gaining ground. Scangos attributed the resurgence largely to its Avonex Pen auto-injector. 

The potential exists for Tysabri, Biogen's second-biggest drug, to become an even larger revenue source. A phase 3 study is under way for use of Tysabri in treating secondary progressive multiple sclerosis, which impacts around 35% of multiple sclerosis patients and has no approved drug treatment. Results from the trial are expected in 2015.  

The FDA makes its decision on another multiple sclerosis drug, BG12, in less than three months. The company is ready for a commercial launch in the second quarter of 2013 pending approval.

Other drugs in the pipeline include two hemophilia compounds: recombinant Factor VIII, for which regulatory approval should be filed in the first half of 2013, and recombinant Factor IX, for which a Biologic License Application was submitted in  late 2012. The company also anticipates phase 3 results for PEG Interferon Beta-1A in the first half of this year. Results from a phase 3 study of daclizumab HYP, another multiple sclerosis drug developed in partnership with AbbVie (NYSE: ABBV  ) , are expected in 2014.

Celgene (NASDAQ: CELG  )
Celgene provided upbeat product and financial updates. CEO Bob Hugin announced 2012 earnings should come in at the high end of previous guidance. He also projected sales growth over the next five years at a 19% compounded annual growth rate.

The company's leading product, Revlimid, continues to do well. Celgene expects approval in China for Revlimid in the near term and is working on approval for myelodisplatic syndromes in Europe. 

However, Celgene's new products excited Hugin the most. The FDA makes its approval decision for Pomalyst in treating relapsed refractory myeloma on Feb. 10. The company hopes for European approval by end of 2013.

Hugin spoke about several recent pipeline success stories. Positive results were found for Abraxane in treating melanoma and, even more importantly, pancreatic cancer. Possibly even bigger news came from apremilast, for which Celgene will submit for regulatory approval after strong phase 3 results in multiple studies.

Gilead Sciences (NASDAQ: GILD  )
Gilead's CEO John Martin emphasized the launches of two HIV products in 2012: Complera, which launched in developed markets, and Stribild, which launched in the U.S. in August. Martin noted that Complera's launch was impressive, but prescriptions for Stribild are 70% higher than Complera during the same time period. Gilead expects European approval for Stribild this quarter.

A promising drug in the company's HIV pipeline is its nucleotide reverse transcriptase inhibitor TAF. The drug advances to a phase 3 study this year. Martin heaped praise on sofosbuvir, a hepatitis C drug for which phase 3 studies are under way. Gilead intends to submit a New Drug Application in the second quarter.

Martin also discussed Gilead's oncology program. Of particular note was idelalisib, which is in a phase 3 study for treating chronic lymphocytic leukemia and a phase 2 study targeting indolent non-Hodgkin's lymphoma.  

And the winner is...
Gilead was the biggest winner for investors in 2012, with shares surging 75%. Celgene came in last position among our top four.

AMGN Chart

AMGN data by YCharts.

My view is that investors really can't go wrong with any of these stocks. However, I like Celgene the most because of the strength of its new products. The company's presentation this week spurred a 12% rally that I suspect will continue. With solid potential for more drug approvals in the near future, Celgene looks to be the best big biotech for 2013. 

With Celgene's broad portfolio of drugs and a strong pipeline to boot, many investors see it as a smarter way to play the biotech investing game. While Celgene might be a safer stock than its small biotech brethren, investors need to know about the key opportunities and risks facing the company. We run through them all in The Motley Fool's brand new premium report on Celgene. To claim your copy today, simply click here now.


Read/Post Comments (1) | Recommend This Article (2)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On January 09, 2013, at 4:51 PM, biotech101invest wrote:

    Celgene is still inexpensive by many measures vs these other biotech stocks like BIIB and AMGN and GILD. Still under a 1.0 PEG ratio & not expensive at all. Best EPS growth in ALL of biotech - near the tops in the ENTIRE S&P 500. And even with all the good news there are still MANY very big near term catalysts coming.

    It is now apparent that CELG will have 5 separate billion $ a yr drugs.

    People underestimated Abraxane – then CELG got lung cancer approval, stunning melanoma and Pancreatic Cancer top line that could make this the standard of care in this difficult disease. Some didn't believe in Apremilast - they said its impossible to have an oral PDE4 inhibitor without serious GI side effects. They forgot about oral aza and the rest of the pipeline. And they are STILL underestimating Pomalidomide as well as International Revlimid sales and Non-Meloma Revlimid sales. The pipeline is still seriously undervalued at the current PPS. They continue to miss the "earning leverage story" as international sales ramp with industry high margins and industry low tax rates combined with a world class buyback/capital plan.

    So what was the turning point Monday at JP Morgan healthcare conf– sure the $13-$14 EPS in 2017 helps as at even a 0.90 PEG ratio (1.0 is standard) that is a $292.50-$315 stock in 2017 discounted back. This stock is still cheap.

    But to me what was of paramount importance was the Apremilast news. Most of us were expecting only Esteem 1 results but CEO Hugin delivered a stunner as “breaking news” that they had BOTH Esteem 1 and Esteem 2 trial results – 2 Phase 3 trials with an impressive 1250 patients and the key word was HIGHLY statistically significant with positive safety profile consistent with the THREE PsA Ph 3 trials and EVEN better than the Phase 2 positive safety results. Then after reading the Apremilast PR investors started to realize that the endpoint is PASI 75 – which if you talk to dermatologists is a pretty high bar and HIGHLY stat sig over this bar is amazing for an oral PDE-4 inhibitor. When you look at tthe side effects of Enbrel – you wonder why anyone would ever again take Enbrel before at least trying Apremilast once approved.

    In addition the comments on EU front line and what is in the long term guidance exudes confidence in Pomalidomide, Apremilast, Abraxane Pancreatic Cancer detailed data coming and MM-020 coming results.

    Before this weeks move this stock had not reacted to all the positive news in the second half of 2012 but this is only the beginning with MANY big catalysts still to come including: China/Mexico/Brazil/South Korea/Russia Revlimid approvals, Pomalidomide approval, MM-020 data, detail Pancreatic Cancer OS data Jan 25th at ASCO GI, and more. Yes the stock is still cheap by almost any measure. Its still under a 1.0 PEG ratio. Its at a ridiculous discount to 3 or 5 yr discounted cash flow or discounted earnings stream. And it still does not reflect the value of this companies pipeline, strong margins, amazing cash flow and now world class capital plan completing the third leg of the stool thanks to our superstar CFO. Ms Jackie Fouse is the best CFO in all of biotech and CEO Hugin has assembled one of the best biotech executive teams in the world.

    No wonder Piper just upgraded to Overweight and raised its target from $86 to $111 after Monday's CELG update. Benstein also increased its target to $106. Both say that is on conservative ests as well.

Add your comment.

DocumentId: 2187596, ~/Articles/ArticleHandler.aspx, 4/20/2014 9:32:13 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement